Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LENZ

LENZ Therapeutics Inc

Oct 27 • 04:00PM ET

31.29

-0.68 -2.13 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BMY GILD REGN VRTX BIIB NBIX ALNY BMRN IONS

| Held by: VTI IWM VXF IBB IWO VTWO SCHA XPH DWAS VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.90	Insider Own	14.45%	Shs Outstand	28.50M	Perf Week	-13.83%
Market Cap	892.46M	Forward P/E	-	EPS next Y	-2.52	Insider Trans	-31.39%	Shs Float	24.40M	Perf Month	-25.55%
Enterprise Value	683.88M	PEG	-	EPS next Q	-0.69	Inst Own	92.49%	Short Float	23.18%	Perf Quarter	-1.20%
Income	-52.40M	P/S	178.49	EPS this Y	-10.58%	Inst Trans	14.21%	Short Ratio	7.46	Perf Half Y	14.72%
Sales	5.00M	P/B	4.32	EPS next Y	2.54%	ROA	-24.95%	Short Interest	5.66M	Perf YTD	8.38%
Book/sh	7.24	P/C	4.26	EPS next 5Y	62.83%	ROE	-26.25%	52W High	50.40 -37.92%	Perf Year	23.68%
Cash/sh	7.35	P/FCF	-	EPS past 3/5Y	35.06% -181.63%	ROIC	-25.32%	52W Low	16.53 89.23%	Perf 3Y	100.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	98.20%	Volatility	8.49% 7.82%	Perf 5Y	-
Dividend TTM	-	EV/Sales	136.78	EPS Y/Y TTM	79.90%	Oper. Margin	-1239.16%	ATR (14)	2.80	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	20.54	Sales Y/Y TTM	-	Profit Margin	-1047.96%	RSI (14)	31.69	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	20.54	EPS Q/Q	-32.64%	SMA20	-23.17%	Beta	0.53	Target Price	54.12
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-22.66%	Rel Volume	1.31	Prev Close	31.97
Employees	42	LT Debt/Eq	0.00	Earnings	Jul 30 BMO	SMA200	1.79%	Avg Volume	757.88K	Price	31.29
IPO	Jun 25, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.14% 599.99%	Trades		Volume	980,927	Change	-2.13%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-14-25	Resumed	Piper Sandler	Overweight	$38 → $51
Mar-18-25	Initiated	TD Cowen	Buy	$60
Sep-27-24	Initiated	Raymond James	Outperform	$37
Aug-12-24	Initiated	H.C. Wainwright	Buy	$38
Apr-15-24	Initiated	William Blair	Outperform
Apr-15-24	Initiated	Leerink Partners	Outperform	$32
Apr-10-24	Initiated	Citigroup	Buy	$34
Mar-27-24	Initiated	Piper Sandler	Overweight	$28
Feb-23-23	Downgrade	Cowen	Outperform → Market Perform
Feb-23-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$3
Feb-23-23	Downgrade	BofA Securities	Neutral → Underperform	$3 → $2
Jan-25-23	Downgrade	BTIG Research	Buy → Neutral
Jan-18-23	Downgrade	BofA Securities	Buy → Neutral	$7 → $3
Jan-06-23	Downgrade	SVB Leerink	Outperform → Mkt Perform	$11 → $2
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$14 → $7
Sep-15-22	Initiated	Cantor Fitzgerald	Overweight	$12
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$12
Apr-14-22	Initiated	BTIG Research	Buy	$18
Mar-22-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19 → $8
Feb-18-22	Initiated	RBC Capital Mkts	Sector Perform	$11

Show Previous Ratings

Oct-22-25 12:00PM	LENZ Therapeutics, Inc. (LENZ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Sep-30-25 08:05AM	LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States (PR Newswire)
Sep-26-25 05:56PM	Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors (Barrons.com) +6.80%
Sep-22-25 03:43AM	Jim Cramer Says "LENZ Therapeutics Has a Promising Story" (Insider Monkey)
Sep-10-25 02:15AM	What One Top Small-Cap Growth Fund Is Buying Now (Barrons.com)
04:30PM	Loading…
Aug-29-25 04:30PM	Core Scientific, NewAmsterdam Pharma, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-25-25 08:00AM	LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences (GlobeNewswire)
Jul-31-25 04:05PM	LENZ Therapeutics Announces US FDA Approval of VIZZ for the Treatment of Presbyopia (GlobeNewswire)
Jul-30-25 09:10AM	LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss (Zacks)
08:00AM	LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Jul-28-25 08:00AM	LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia (GlobeNewswire)
Jul-25-25 04:44PM	Dell, Bitfarms, Bloom Energy, and More Stocks See Action From Activist Investors (Barrons.com) -5.33%
Jul-22-25 10:50AM	Phase II and Phase III Catalyst Monitor: Q3 2025 Outlook Report - Upcoming FDA Decisions Drive Momentum in Biopharma with Key Catalysts Across GHD, PKU, Presbyopia, and Wet AMD Treatments (GlobeNewswire)
Jul-16-25 12:00PM	LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy? (Zacks) +7.45%
Jul-15-25 09:55AM	Does LENZ Therapeutics, Inc. (LENZ) Have the Potential to Rally 30.86% as Wall Street Analysts Expect? (Zacks)
08:00AM	Loading…
Jul-07-25 08:00AM	LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada (GlobeNewswire)
08:00AM	LENZ Therapeutics and Laboratoires Thea Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada (GlobeNewswire)
Jul-03-25 04:06PM	Warner Bros., Cidara, LENZ Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com) +5.07%
May-27-25 08:00AM	LENZ Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-09-25 09:03AM	LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia (GlobeNewswire)
May-07-25 04:05PM	LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-06-25 04:30PM	LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference (GlobeNewswire) -11.03%
Apr-30-25 04:30PM	LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025 (GlobeNewswire) +7.08%
Apr-07-25 08:00AM	LENZ Therapeutics: Freedom From Reading Glasses (Seeking Alpha) -7.93%
Apr-01-25 07:00AM	Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-27-25 05:33PM	LENZ Therapeutics Stock Is Attractive Before PDUFA (SeekingAlpha)
Mar-19-25 08:09PM	Lenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progress (SeekingAlpha)
08:09PM	LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:05PM	LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-11-25 08:00AM	LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 (GlobeNewswire)
08:00AM	Loading…
Mar-03-25 08:00AM	LENZ Therapeutics to Host Commercial Day on April 15, 2025 (GlobeNewswire)
Feb-24-25 08:00AM	LENZ Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 08:00AM	LENZ Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-06-24 07:00AM	LENZ Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire) +12.50%
Oct-30-24 08:00AM	LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 (GlobeNewswire)
Oct-27-24 09:00PM	CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 (GlobeNewswire)
Oct-22-24 08:10AM	Lenz Therapeutics announces FDA acceptance of NDA for LNZ100 (TipRanks) -9.27%
Oct-21-24 08:00AM	LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia (GlobeNewswire)
Sep-30-24 08:00AM	LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences (GlobeNewswire)
Aug-27-24 04:01PM	LENZ Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 04:05PM	LENZ Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-12-24 08:00AM	LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia (GlobeNewswire)
Aug-07-24 04:01PM	LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 (GlobeNewswire)
Jul-15-24 08:00AM	LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital (GlobeNewswire)
Jun-10-24 08:00AM	LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024 (GlobeNewswire) +14.18%
May-30-24 08:00AM	LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-24 09:03AM	LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 04:01PM	LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-01-24 04:01PM	LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024 (GlobeNewswire)
Apr-03-24 07:00AM	LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials (Business Wire)
Apr-02-24 04:01PM	LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials (Business Wire)
Mar-21-24 04:30PM	LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress (Business Wire) +7.64%
10:09AM	11 Stocks that Paid Special Dividends in 2024 (Insider Monkey)
Mar-08-24 05:00PM	Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics (Business Wire) +18.79%
Mar-01-24 10:48AM	Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm (GlobeNewswire)
Feb-02-24 11:58AM	Kuehn Law Encourages DSKE, RYZB, ROVR, and GRPH Investors to Contact Law Firm (GlobeNewswire)
Jan-27-24 12:07PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates FNCB, PWFL, DOC, GRPH (GlobeNewswire)
Nov-16-23 12:00PM	What Makes Graphite Bio, Inc. (GRPH) a New Buy Stock (Zacks)
Nov-15-23 07:00AM	LENZ Therapeutics and Graphite Bio Announce Merger Agreement (Business Wire)
Jun-23-23 07:00AM	Graphite Bio Announces Departure of Chief Financial Officer (Business Wire)
May-15-23 07:44AM	Graphite Bio, Inc.'s (NASDAQ:GRPH) largest shareholders are private equity firms with 43% ownership, institutions own 22% (Simply Wall St.) +6.02%
May-10-23 10:18AM	Should You Buy Graphite Bio (GRPH) Ahead of Earnings? (Zacks)
Apr-26-23 02:10PM	12 Gene Editing Stocks With the Best Long-Term Potential (Insider Monkey)
Mar-29-23 04:20PM	11 Most Promising Gene Editing Stocks According to Analysts (Insider Monkey)
Mar-25-23 10:12AM	We're Keeping An Eye On Graphite Bio's (NASDAQ:GRPH) Cash Burn Rate (Simply Wall St.)
Mar-20-23 04:05PM	Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results (Business Wire)
Feb-23-23 05:36PM	Sickle-cell gene therapy developer stops program, cuts half of staff (American City Business Journals) +15.91%
Feb-22-23 04:05PM	Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring (Business Wire)
Jan-10-23 09:35AM	Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround (Zacks)
Jan-06-23 05:54PM	Two Covid-era biotech IPOs Spruce and Graphite Bio see stock head in different directions (American City Business Journals) -39.54%
09:07AM	Graphite Bio Shares Tank After Pausing Sickle Cell Therapy Study (Benzinga)
Jan-05-23 05:57PM	Graphite Bio pauses early-stage blood disease therapy trial (Reuters)
04:05PM	Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease (Business Wire)
Dec-11-22 10:00AM	Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting (Business Wire)
Nov-21-22 08:00AM	Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference (Business Wire)
Nov-17-22 09:45AM	2 Strong Buy Penny Stocks That Could See 200% Gains (Or More) (TipRanks)
Nov-09-22 04:05PM	Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results (Business Wire)
Nov-03-22 09:05AM	Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition (Business Wire)
Oct-16-22 08:33AM	Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation (Simply Wall St.)
Oct-11-22 08:00AM	Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention (Business Wire)
Sep-06-22 08:00AM	Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference (Business Wire)
Aug-30-22 05:47PM	Potential sickle cell disease 'cure' jumps to clinic, yet investors remain cool (American City Business Journals)
Aug-11-22 04:05PM	Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results (Business Wire) +5.03%
08:16AM	Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease (Business Wire)
Jun-17-22 02:26PM	BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock (Benzinga) +12.15%
Jun-01-22 08:00AM	Graphite Bio Announces Participation in Jefferies Healthcare Conference (Business Wire)
May-29-22 02:15PM	I'm 'Following Up' on a Biotech Trade With Attractive Potential (TheStreet.com)
May-16-22 06:00AM	Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting (Business Wire)
May-12-22 04:05PM	Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results (Business Wire) +14.04%
May-09-22 08:13AM	Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.) -19.44%
May-04-22 08:00AM	Graphite Bio Announces Participation in Upcoming Investor Conferences (Business Wire) +6.22%
May-03-22 08:00AM	Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease (Business Wire)
May-02-22 04:38PM	Graphite Bio Announces Participation in the ASGCT 25th Annual Meeting Including Oral Presentation About Beta-thalassemia Program (Business Wire)
Mar-28-22 08:00AM	Graphite Bio Announces Participation in H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference (Business Wire)
Mar-23-22 12:28PM	Insiders who purchased Graphite Bio, Inc. (NASDAQ:GRPH) earlier this year lose an additional US$64k as the stock sinks to US$6.16 (Simply Wall St.) -8.60%
08:00AM	Graphite Bio Announces Formation of Scientific Advisory Board (Business Wire)
Mar-21-22 08:25AM	Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results (Business Wire) -15.15%
Mar-03-22 08:00AM	Graphite Bio Announces Participation in Upcoming Cowen 42nd Annual Health Care Conference (Business Wire)
Mar-02-22 08:00AM	Graphite Bio Appoints Alethia Young as Chief Financial Officer (Business Wire)
Feb-08-22 10:20AM	Is a Surprise Coming for Graphite Bio (GRPH) This Earnings Season? (Zacks)

LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia. The company was founded by James W. McCollum in July 2013 and is headquartered in Solana Beach, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Versant Venture Capital VI, L.	10% Owner	Sep 30 '25	Sale	46.01	132,944	6,117,323	1,050,599	Oct 02 04:40 PM
Versant Venture Capital VI, L.	10% Owner	Sep 30 '25	Sale	46.01	92,030	4,234,695	764,127	Oct 02 04:40 PM
Versant Venture Capital VI, L.	10% Owner	Sep 18 '25	Sale	42.23	90,654	3,828,632	1,183,543	Sep 22 04:23 PM
Versant Venture Capital VI, L.	10% Owner	Sep 18 '25	Sale	42.23	44,650	1,885,724	856,157	Sep 22 04:23 PM
Versant Venture Capital VI, L.	10% Owner	Aug 25 '25	Sale	39.54	52,419	2,072,738	1,321,640	Aug 26 07:59 PM
Versant Venture Capital VI, L.	10% Owner	Aug 26 '25	Sale	39.01	47,443	1,850,891	1,274,197	Aug 26 07:59 PM
Versant Venture Capital VI, L.	10% Owner	Aug 22 '25	Sale	40.15	26,161	1,050,392	1,374,059	Aug 26 07:59 PM
Versant Venture Capital VI, L.	10% Owner	Aug 25 '25	Sale	39.54	25,818	1,020,888	924,175	Aug 26 07:59 PM
Versant Venture Capital VI, L.	10% Owner	Aug 26 '25	Sale	39.01	23,368	911,655	900,807	Aug 26 07:59 PM
Versant Venture Capital VI, L.	10% Owner	Aug 22 '25	Sale	40.15	12,885	517,356	949,993	Aug 26 07:59 PM
Versant Venture Capital VI, L.	10% Owner	Aug 15 '25	Sale	39.50	145,051	5,729,514	1,430,848	Aug 19 04:51 PM
Versant Venture Capital VI, L.	10% Owner	Aug 15 '25	Sale	39.50	69,949	2,762,986	977,963	Aug 19 04:51 PM
Versant Venture Capital VI, L.	10% Owner	Aug 18 '25	Sale	38.56	30,628	1,181,049	1,400,220	Aug 19 04:51 PM
Versant Venture Capital VI, L.	10% Owner	Aug 18 '25	Sale	38.56	15,085	581,694	962,878	Aug 19 04:51 PM
Versant Venture Capital VI, L.	10% Owner	Jul 10 '25	Sale	34.00	191,376	6,506,784	1,575,899	Jul 14 04:50 PM
Versant Venture Capital VI, L.	10% Owner	Jun 27 '25	Sale	30.46	200,000	6,093,000	1,767,275	Jul 01 06:16 PM
Versant Venture Capital VI, L.	10% Owner	Jun 20 '25	Sale	30.25	133,924	4,051,201	1,967,275	Jun 20 05:50 PM
Versant Venture Capital VI, L.	10% Owner	Jun 20 '25	Sale	30.35	100,877	3,061,617	1,047,912	Jun 20 05:50 PM
Versant Venture Capital VI, L.	10% Owner	Jun 18 '25	Sale	29.95	100,000	2,995,000	1,148,789	Jun 20 05:50 PM
Versant Venture Capital VI, L.	10% Owner	Jun 10 '25	Sale	29.00	350,000	10,150,000	1,248,789	Jun 12 04:37 PM
Olsson Shawn	Chief Commercial Officer	Apr 09 '25	Option Exercise	2.08	1,400	2,912	4,733	Apr 09 07:20 PM
Schimmelpennink Evert B.	President, CEO and Secretary	Mar 07 '25	Option Exercise	1.04	4,200	4,368	49,200	Mar 07 06:10 PM
Olsson Shawn	Chief Commercial Officer	Dec 16 '24	Option Exercise	2.08	3,333	6,933	3,333	Dec 17 07:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LENZ

LENZ Therapeutics Inc

Upgrade your FINVIZ experience